Sign inJoin waitlistJoin the waitlist

Chakradhar Reddy

Clinical Assistant Professor | Hepatology and General Gastroenterology · East Tennessee State University/Quillen College of Medicine

Credentials: · · · · · · ·

History

East Tennessee State University/Quillen College of Medicine
Present

Transplant Hepatology
2005–2006
University Of Miami Hospitals & Clinics
2002–2005
Internal Medicine
Wright State University Boonshoft School of Medicine
1999–2002
Kurnool Medical College
1995–1999

Research

Acute pancreatitis: Trends in outcomes and the role of acute kidney injury in mortality- A propensity-matched analysis
Pancreatology · 2018 · Last of 6 authors · 65 citations
Peri-Procedural Aggressive Hydration for Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis Prophylaxsis: Meta-analysis of Randomized Controlled Trials
Systematic review or meta-analysis · Pancreatology · 2019 · Last of 7 authors · 50 citations
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - A systematic review and network meta-analysis
Systematic review or meta-analysis · European Journal of Gastroenterology & Hepatology · 2021 · Last of 4 authors · 41 citations

Kalpit Devani
12 papers · 9 as a fellow
Mark Young
12 papers
Dhruvil Radadiya
9 papers · 9 as a resident
Paris Charilaou
7 papers · 7 as a fellow
Bhaumik Brahmbhatt
5 papers
EA
Edward Arsura
5 papers
RB
Ravi Bobba
4 papers
DC
Dhara Chaudhari
3 papers · 3 as a resident
Don Rockey
3 papers
AK
Aaysha Kapila
2 papers · 2 as a resident
PJ
Palashkumar Jaiswal
2 papers · 2 as a resident
Royce Johnson
2 papers

Clinical trials

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Principal investigator · Terminated · Phase 3
University of Miami
2006–2008
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
Site PI · Recruiting · Phase 2
GlaxoSmithKline
2026–2027
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Site PI · Recruiting · Phase 2
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
2024–2030